381 related articles for article (PubMed ID: 27226774)
1. Screening for Fabry Disease by Urinary Globotriaosylceramide Isoforms Measurement in Patients with Left Ventricular Hypertrophy.
Gaggl M; Lajic N; Heinze G; Voigtländer T; Sunder-Plassmann R; Paschke E; Fauler G; Sunder-Plassmann G; Mundigler G
Int J Med Sci; 2016; 13(5):340-6. PubMed ID: 27226774
[TBL] [Abstract][Full Text] [Related]
2. Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients.
Abaoui M; Boutin M; Lavoie P; Auray-Blais C
Clin Chim Acta; 2016 Jan; 452():191-8. PubMed ID: 26593248
[TBL] [Abstract][Full Text] [Related]
3. High-Risk Screening of Fabry Disease: Analysis of Fifteen Urinary Methylated and Non-Methylated Gb
Abaoui M; Boutin M; Lavoie P; Auray-Blais C
Curr Protoc Hum Genet; 2016 Oct; 91():17.24.1-17.24.11. PubMed ID: 27727434
[TBL] [Abstract][Full Text] [Related]
4. Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma.
Ferreira S; Auray-Blais C; Boutin M; Lavoie P; Nunes JP; Martins E; Garman S; Oliveira JP
Clin Chim Acta; 2015 Jul; 447():96-104. PubMed ID: 26070511
[TBL] [Abstract][Full Text] [Related]
5. Plasma Globotriaosylsphingosine Level as a Primary Screening Target for Fabry Disease in Patients With Left Ventricular Hypertrophy.
Yamashita S; Saotome M; Satoh H; Kajihara J; Mochizuki Y; Mizuno K; Nobuhara M; Miyajima K; Kumazawa A; Tominaga H; Takase H; Tawarahara K; Wakahara N; Matsunaga M; Wakabayashi Y; Matsumoto Y; Terada H; Sano M; Ohtani H; Urushida T; Hayashi H; Ishii S; Maruyama H; Maekawa Y
Circ J; 2019 Aug; 83(9):1901-1907. PubMed ID: 31308318
[TBL] [Abstract][Full Text] [Related]
6. The prevalence of Fabry disease among 1009 unrelated patients with hypertrophic cardiomyopathy: a Russian nationwide screening program using NGS technology.
Savostyanov K; Pushkov A; Zhanin I; Mazanova N; Trufanov S; Pakhomov A; Alexeeva A; Sladkov D; Asanov A; Fisenko A
Orphanet J Rare Dis; 2022 May; 17(1):199. PubMed ID: 35578305
[TBL] [Abstract][Full Text] [Related]
7. Interfering parameters in the determination of urinary globotriaosylceramide (Gb3) in patients with chronic kidney disease.
Gaggl M; Hofer M; Weidner S; Kleinert J; Fauler G; Wallner M; Kotanko P; Paschke E; Sunder-Plassmann G
J Nephrol; 2015 Dec; 28(6):679-89. PubMed ID: 25857295
[TBL] [Abstract][Full Text] [Related]
8. Urinary total globotriaosylceramide and isoforms to identify women with Fabry disease: a diagnostic test study.
Paschke E; Fauler G; Winkler H; Schlagenhauf A; Plecko B; Erwa W; Breunig F; Urban W; Vujkovac B; Sunder-Plassmann G; Kotanko P
Am J Kidney Dis; 2011 May; 57(5):673-81. PubMed ID: 21186071
[TBL] [Abstract][Full Text] [Related]
9. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance.
Smid BE; van der Tol L; Cecchi F; Elliott PM; Hughes DA; Linthorst GE; Timmermans J; Weidemann F; West ML; Biegstraaten M; Lekanne Deprez RH; Florquin S; Postema PG; Tomberli B; van der Wal AC; van den Bergh Weerman MA; Hollak CE
Int J Cardiol; 2014 Dec; 177(2):400-8. PubMed ID: 25442977
[TBL] [Abstract][Full Text] [Related]
10. Risk of death in heart disease is associated with elevated urinary globotriaosylceramide.
Schiffmann R; Forni S; Swift C; Brignol N; Wu X; Lockhart DJ; Blankenship D; Wang X; Grayburn PA; Taylor MR; Lowes BD; Fuller M; Benjamin ER; Sweetman L
J Am Heart Assoc; 2014 Feb; 3(1):e000394. PubMed ID: 24496231
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of Fabry disease in a predominantly hypertensive population with left ventricular hypertrophy.
Terryn W; Deschoenmakere G; De Keyser J; Meersseman W; Van Biesen W; Wuyts B; Hemelsoet D; Pascale H; De Backer J; De Paepe A; Poppe B; Vanholder R
Int J Cardiol; 2013 Sep; 167(6):2555-60. PubMed ID: 22805550
[TBL] [Abstract][Full Text] [Related]
12. Globotriaosylsphingosine (Lyso-Gb
Alharbi FJ; Baig S; Auray-Blais C; Boutin M; Ward DG; Wheeldon N; Steed R; Dawson C; Hughes D; Geberhiwot T
J Inherit Metab Dis; 2018 Mar; 41(2):239-247. PubMed ID: 29294190
[TBL] [Abstract][Full Text] [Related]
13. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry.
Auray-Blais C; Blais CM; Ramaswami U; Boutin M; Germain DP; Dyack S; Bodamer O; Pintos-Morell G; Clarke JT; Bichet DG; Warnock DG; Echevarria L; West ML; Lavoie P
Clin Chim Acta; 2015 Jan; 438():195-204. PubMed ID: 25149322
[TBL] [Abstract][Full Text] [Related]
14. Cardiac manifestations of Fabry disease in G3Stg/GlaKO and GlaKO mouse models-Translation to Fabry disease patients.
Kugadas A; Artoni P; Ruangsiriluk W; Zhao M; Boukharov N; Islam R; Volfson D; Derakhchan K
PLoS One; 2024; 19(5):e0304415. PubMed ID: 38820517
[TBL] [Abstract][Full Text] [Related]
15. Screening for Fabry Disease in patients with unexplained left ventricular hypertrophy.
Sadasivan C; Chow JTY; Sheng B; Chan DKH; Fan Y; Choi PCL; Wong JKT; Tong MMB; Chan TN; Fung E; Kam KKH; Chan JYS; Chi WK; Paterson DI; Senaratne M; Brass N; Oudit GY; Lee APW
PLoS One; 2020; 15(9):e0239675. PubMed ID: 32987398
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy.
Kubo T; Ochi Y; Baba Y; Hirota T; Tanioka K; Yamasaki N; Yoshimitsu M; Higuchi K; Takenaka T; Nakajima K; Togawa T; Tsukimura T; Sano S; Tei C; Sakuraba H; Kitaoka H
J Cardiol; 2017 Jan; 69(1):302-307. PubMed ID: 27554049
[TBL] [Abstract][Full Text] [Related]
17. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.
Rombach SM; Aerts JM; Poorthuis BJ; Groener JE; Donker-Koopman W; Hendriks E; Mirzaian M; Kuiper S; Wijburg FA; Hollak CE; Linthorst GE
PLoS One; 2012; 7(10):e47805. PubMed ID: 23094092
[TBL] [Abstract][Full Text] [Related]
18. An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring.
Rozenfeld PA; De Francesco NP; Borrajo GJ; Ceci R; Fossati CA
Clin Chim Acta; 2009 May; 403(1-2):194-7. PubMed ID: 19268437
[TBL] [Abstract][Full Text] [Related]
19. [Contribution of the measurement of globotriaosylceramide in urine to the diagnosis and follow-up of Fabry disease].
Piraud M; Maire I; Froissart R
Rev Med Interne; 2010 Dec; 31 Suppl 2():S270-4. PubMed ID: 21211678
[TBL] [Abstract][Full Text] [Related]
20. Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease.
Auray-Blais C; Cyr D; Ntwari A; West ML; Cox-Brinkman J; Bichet DG; Germain DP; Laframboise R; Melançon SB; Stockley T; Clarke JT; Drouin R
Mol Genet Metab; 2008 Mar; 93(3):331-40. PubMed ID: 18023222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]